Mito Biopharma

Mito Biopharma is a biotechnology company focused on developing first-in-class mitochondrial uncouplers for the treatment of metabolic diseases. The company's lead program, MB101, is a small molecule designed to increase basal metabolic rate by safely uncoupling oxidative phosphorylation. This approach aims to promote weight loss and improve insulin sensitivity in patients with obesity and type 2 diabetes. Additionally, the company is exploring the potential of its technology in treating metabolic dysfunction-associated steatohepatitis (MASH). Mito Biopharma's proprietary delivery methods are engineered to provide tissue-specific activity, reducing the risk of systemic toxicity. Founded as a spin-off from Purdue University, the company leverages cutting-edge research in mitochondrial biology and drug delivery.